

www.immunoway.com

GHR Rabbit pAb

CatalogNo: YT5573

Key Features

Host Species

Rabbit

Reactivity

Human,Mouse,Rat

ApplicationsWB,ELISA

MW • 140kD (Observed) Isotype • IgG

Recommended Dilution Ratios

WB 1:500-1:2000 ELISA 1:10000 Not yet tested in other applications.

Storage

Storage*-15°C to -25°C/1 year(Do not lower than -25°C)FormulationLiquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Basic Information

Clonality Polyclonal

Immunogen Information

ImmunogenThe antiserum was produced against synthesized peptide derived from the N-terminal
region of human GHR. AA range:21-70

Specificity GHR Polyclonal Antibody detects endogenous levels of GHR protein.

Target Information

Gene name GHR

Protein Name Growth hormone receptor

Organism	Gene ID	UniProt ID
Human	<u>2690;</u>	<u>P10912;</u>
Mouse	<u>14600;</u>	<u>P16882;</u>
Rat	<u>25235;</u>	<u>P16310;</u>

CellularCell membrane; Single-pass type I membrane protein. On growth hormone binding, GHR is
ubiquitinated, internalized, down-regulated and transported into a degradative or non-
degradative pathway. .; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.
Remains fixed to the cell membrane and is not internalized.; [Growth hormone-binding
protein]: Secreted. Complexed to a substantial fraction of circulating GH. .

Tissue specificity Expressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. Isoform 1 expression in placenta is predominant in chorion and decidua. Isoform 4 is highly expressed in placental villi. Isoform 2 is expressed in lung, stomach and muscle. Low levels in liver.

Function Disease:Defects in GHR are a cause of Laron dwarfism [MIM:262500]; also known as pituitary dwarfism II; Laron-type pituitary dwarfism I (LTD1) or Laron syndrome (LS). It is the most severe form of growth hormone insensitivity (GHI) characterized by growth impairment, dysmorphic facial features and truncal obesity. Levels of GHBP are low or undetectable in patients with Laron syndrome., Disease: Defects in GHR may be a cause of short stature [MIM:604271]. Short stature is defined by a subnormal rate of arowth..Domain:The box 1 motif is required for IAK interaction and/or activation...Domain:The extracellular domain is the ligand-binding domain representing the growth hormone-binding protein (GHBP)., Domain: The ubiquitination-dependent endocytosis motif (UbE) is required for recruitment of the ubiquitin conjugation system on to the receptor and for its internalization.,Domain:The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.,Function:Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling., Function: Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway.,Function:The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.,polymorphism:Genetic variation in GHR may act as phenotype modifier in familial hypercholesterolemia [MIM:143890] patients carrying a mutation in the LDLR gene., PTM: On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2., PTM:On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiguitination is not sufficient for GHR internalization., PTM: The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding to the receptor probably due to a conformational change in GHR rendering the receptor inaccessible to ADAM17., similarity: Belongs to the type I cytokine receptor family. Type 1 subfamily., similarity: Contains 1 fibronectin type-III domain., subcellular location: On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway., subcellular location:Remains fixed to the cell membrane and is not internalized.,subunit:On growth hormone (GH) binding, forms homodimers and binds JAK2 via a box 1-containing domain (By similarity). Binding to SOCS3 inhibits JAK2 activation, binding to CIS and SOCS2 inhibits STAT5 activation (By similarity). Interacts with ADAM17.,tissue specificity:Expressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. In the placenta, isoform 1 predominantly expressed in chorion and decidua, isoform 4 highly expressed in villi. Isoform 2 is expressed in lung, stomach and muscle. Low levels in liver.,

Validation Data



Western Blot analysis of SKOV3 cells using GHR Polyclonal Antibody. Secondary antibody(catalog#:RS0002) was diluted at 1:20000

Contact information

order@immunoway.com	
tech@immunoway.com	
877-594-3616 (Toll Free), 408-747-0185	
http://www.immunoway.com	
2200 Ringwood Ave San Jose, CA 95131 USA	



Please scan the QR code to access additional product information: **GHR Rabbit pAb**

For Research Use Only. Not for Use in Diagnostic Procedures.

Antibody | ELISA Kits | Protein | Reagents